Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Cibula, D; Akilli, H; Jarkovsky, J; van, Lonkhuijzen, L; Scambia, G; Meydanli, MM; Ortiz, DI; Falconer, H; Abu-Rustum, NR; Odetto, D; Klát, J; Dos, Reis, R; Zapardiel, I; Di, Martino, G; Presl, J; Laky, R; López, A; Weinberger, V; Obermair, A; Pareja, R; Poncová, R; Mom, C; Bizzarri, N; Borčinová, M; Aslan, K; Salcedo, Hernandez, RA; Fons, G; Benešová, K; Dostálek, L; Ayhan, A.
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
Gynecol Oncol. 2023; 170: 195-202. Doi: 10.1016/j.ygyno.2023.01.014
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Laky Rene Walter
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
OBJECTIVE: The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. METHODS: We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. RESULTS: Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size ≥4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). CONCLUSION: Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.

Find related publications in this database (Keywords)
Cervical cancer
Intermediate risk
GOG criteria
Radial surgery
Adjuvant treatment
Radiotherapy
© Med Uni Graz • Impressum